The classical myeloproliferative neoplasms (MPNs), specifically chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …

The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …

We conducted a large international nested case-control study including 1881 patients with
Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n= 647) were patients …

Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in
JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood …

Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of
myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N= 2233), phase 3b …

Infections are a common complication in patients with many hematologic malignancies,
however, whether patients with myeloproliferative neoplasms (MPN) also are at an …

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without
JAK inhibitor therapy | Blood | American Society of Hematology Skip to Main Content …

The Philadelphia-negative myeloproliferative neoplasms (MPNs) are malignancies of the
hematopoietic stem cell (HSC) arising as a consequence of clonal proliferation driven by …

One out of ten patients with Philadelphia‐negative myeloproliferative neoplasms (MPN)
develop a second cancer (SC): in such patients we aimed at assessing the survival impact of …

In recent years, the use of recombinant interferon-alpha (rIFNα) as the initial treatment of the
myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and …